Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Pathology Research Laboratory, |
RCV001542150 | SCV001760818 | pathogenic | Deafness-lymphedema-leukemia syndrome; GATA2 deficiency with susceptibility to MDS/AML | 2021-07-06 | criteria provided, single submitter | curation | PVS1, PS4_Moderate, PM2 |
Labcorp Genetics |
RCV002570650 | SCV003525357 | pathogenic | Deafness-lymphedema-leukemia syndrome; Monocytopenia with susceptibility to infections | 2022-05-15 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 4 of the GATA2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GATA2 are known to be pathogenic (PMID: 21670465, 23223431). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with clinical features of GATA2-related conditions (PMID: 26022708, 26702063). ClinVar contains an entry for this variant (Variation ID: 1184181). Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 26022708). For these reasons, this variant has been classified as Pathogenic. |